FDA Patient Listening Session on Cutaneous and Systemic Mastocytosis

Session Goals

On Tuesday September 28, 2021, TMS representatives along with members of the mastocytosis community participated in a 90- minute listening session where the impact of living with mastocytosis was discussed with representatives from the U.S. Food and Drug Administration (FDA). The overarching goal of the session was to familiarize the FDA with the aspects of mastocytosis that affect patients and caregivers, and their quality of life, most. The session summary provides a detailed report of the session, complete with quotations from presenters.   

Skip to content